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analysis was 90%.
We initially compared single parameters of PFTs including
corrected diffusion limiting capacity of oxygen (DLCO), forced
expiratory volume in one second (FEV1), forced vital capacity
(FVC), FEV1/FVC ratio, and total lung capacity (TLC) obtained
before and after transplant. Post transplant, all PFT parame-
ters showed some degree of reduction compared to pre-
transplant values. FEV1 and FEV1/FVC were signiﬁcantly
decreased (108 vs 92, P ¼ .04 and 86 vs 80%, P ¼ .04, respec-
tively), with no difference between Caucasian and non-
Caucasians. Overall, median values of corrected DLCOand TLC
prior to and after transplant were only slightly reduced.
However, in non-Caucasian patients a signiﬁcant reduction of
DLCO was observed (93%31 vs 73%11, P ¼ .05).
We analyzed intra-patient changes in DLCO and FEV1 values
and no correlationwas found between these parameters and
the development of chronic GVHD.
This study shows an overall decrease in pulmonary function
in patients without apparent lung disease following a mye-
loablative busulfan-based HSCT. However, a higher risk of
a reduced DLCO was noted only among non-Caucasian
patients. At this time it is not known if this observation is due
to genetic, biologic or environmental causes.
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One hundred twenty-three children from 6 French centers
were evaluated retrospectively for the treatment of steroid-
refractory acute graft-versus-host disease (aGVHD) with
Inolimomab, a murine anti-IL2R.Hematopoietic stem cell transplantations (HSCT) were
performed between 1995 and 2012. Diseases were non
malignant inherited diseases (63%) and hematological
malignancies (37%). Median age was 4, 3 years. Donors were
MRD (27.5%), MUD (32%), mismatch-MUD (13%), Haplo-
identical (20.5%) and Cord Blood (CB) (7%). The graft source
was BM (80%), PBSC (12%) and CB (8%). 37% patients had
a myeloablative conditioning. The median time to aGVHD
was 13 days after HSCT. The baseline grade of aGVHDwas I in
19%, II 45.5%, III 25% and IV 10.5%. The median delay between
aGVHD and Inolimomab was 16 days. The median dose was
0.4mg/kg and the median treatment duration of 27 days.
We observe 55% complete responses and 14% partial
responses for a total response rate of 69% and with no side
effect. Among the responders, 26% relapse. Incidence of
infection during treatment was 19.5%.
A logistic model on complete response provide evidence of
the highpredictive negative effect of the baseline grade [Odds
Ratio (OR): 5.24]. No particular target organwas a signiﬁcant
predictive factor for treatment response or survival. However,
multi-organ involvement predicted worse survival with 34%,
45% and 52% of death for patients with one, two, and three or
more organs involved, respectively (P ¼ .234).
The observed overall survival probability was 59%, with
a median survival time of 463 days. The Overall unadjusted
survivalswere 87%, 77 %, and61%at day 100, 200, andoneyear.
Survival was also signiﬁcantly improved for responders
(Relative Risk: 0.413; P ¼ .002).
As shown by multivariate Cox model, the survival was
signiﬁcantly lower for patients with non malignant inherited
diseases [Hazard Ratio (HR) ¼2.88, P < .001] compared with
hematological malignancies, and female patients were
associated with higher mortality (HR¼1.72 , P¼ .049). For
both response and survival, the success rates were signiﬁ-
cantly increasing with year of transplantation, and non-
signiﬁcant differences were found among centers.
Chronic GVHD (cGVHD) occurred in 56% patients, extensive
in 42%. cGVHD incidence was 78%, 72% , 42% for Non
Responders, Partial Responders and Complete Responders
(Anova, P¼ .017, difference only signiﬁcant between
Complete Responders and the others). Patients with hema-
tological malignancies were observed with signiﬁcantly less
cGHVD (OR¼.29, P¼ .012).
Fifty-one patients died, 17(33%) before day 100 and 34(67%)
after day 100, mostly of infections (55%) and GVHD (51%).
In conclusion, Inolimomab is well tolerated and effective for
steroid-refractory aGVHD in pediatrics. Further randomized
studies are requires to deﬁne the optimum regimen.
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The 2005 NIH Consensus Conference recommended assess-
ment of lung function in patients with chronic graft-versus-
host disease (cGVHD) by both pulmonary function tests
(PFTs) and assessment of pulmonary symptoms. The Chronic
GVHD Consortium has made serial collections of these
measures. Based on prior literature, we hypothesized that
the following subgroups would have higher non-relapse
mortality (NRM) or lower overall survival (OS): 1. Obstructive
lung disease; 2. Higher NIH lung score based on symptoms;
3. Higher Lung Function Score (LFS) based on PFTs; 4. Clinical
diagnosis of bronchiolitis obliterans syndrome (BOS).
Methods: Patients  2 years of age diagnosed with cGVHD
requiring systemic treatment  3 years after transplantation
were assessed every 3-6 months. Available PFT data were
abstracted, including FEV1, forced vital capacity (FVC) and
diffusing capacity of lung for carbon monoxide (DLCO).
Obstructive disease was deﬁned as a decreased FEV1 (tested
at <50%, <75%, <80%) and FEV1/FVC < 0.70. The NIH lung
score of 0-3 was based on the severity of pulmonary symp-
toms with exertion. The LFS was based on FEV1 and DLCO. A
clinical diagnosis of BOS was collected from the clinician-
completed data capture form. Cox regression models were ﬁt
for OS and NRM using a time-varying covariate model for
lung function measures and adjusting for patient and
transplant characteristics and non-lung cGVHD severity.
Results: There were 1591 visits used in this analysis, only
845 (50%) of the visits had recorded PFTs. Obstructive
physiology (FEV1<80%) was found in 184 visits and 54 visits
(6%) had FEV1 <50%. BOS was reported on 122 visits. Median
follow up time was 20.1 mo (range 2.9 e 47.7), and median
survival has not been reached. NIH lung score based on
symptoms was strongly correlated with NRM and OS
(Table 1). The NIH lung score correlated with Karnofsky
performance status (correlation ¼ -0.34), and both had
independent prognostic signiﬁcance in multivariate models.
None of the other measures including obstructive PFTs, LFS,
or the clinician's indicator of BOS, were signiﬁcantly associ-
ated with OS or NRM.
Conclusion: NIH clinical lung score of 0-3 based on pulmo-
nary symptoms is predictive of OS and NRM in patients with
cGVHD. PFT derived data, including the LFS and obstructive
physiology, and a clinical diagnosis of BOS are not associated
with OS or NRM. Our conclusions are limited by inconsistent
practices in performing PFTs.Table




Value n HR, 95% CI
NIH Clinical Lung Score
based on Symptoms
(0-3)
0.007 0 1138 1.0
1 299 2.24 (1.35-3.72)
2 94 1.94 (0.90-4.19)
3 22 3.70 (1.04-13.17)457
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Graft versus host disease (GVHD) remains a principal barrier
to successful outcomes in allogeneic hematopoietic stem cell
transplant (HCT). Corticosteroids are the current standard
initial therapy for acute GVHD with complete responses of
25- 41%. New immunosuppressive strategies are required to
improve acute GVHD management and decrease toxicities of
immunosuppressive agents. We conclude that more effective
acute GVHD therapy may improve survival after allogeneic
HCT. The histone deacetylase inhibitor (HDACi) Vorinostat
has been shown to reduce serum levels of pro-inﬂammatory
cytokines with moderate efﬁcacy in acute GVHD in murine
pre-clinical HCT. We designed a protocol to test the safety
and potential efﬁcacy of a novel HDACi, LBH589, adminis-
tered to patients with acute GVHD within 72 hours of initi-
ation of glucocorticoid therapy (methylprednisolone 0.8 mg/
Kg/day IV or equivalent for at least 14 days) as ﬁrst line
therapy. LBH589 is a potent inhibitor of deacetylases and
HSP90 belonging to a structurally novel class of the cinnamic
hydroxamic acid class of compounds and is one of the most
potent HDACi.We have enrolled n¼9 subjects, median age 52
(39-62 yo), male n¼6/female n¼3, median onset of GVHD
day +34 post HCT (17-108 days) with overall GVHD grade II
(n¼6) or III (n¼3). The ﬁrst three patients were treated with
2.5 mg/m2 intravenously (IV) weekly x4 and a subsequent
subject was treated with 5mg/m2 IV weekly x 4 achieving
GVHD CR (n¼2) and PR (n¼2) on day +8 (after LBH589) and
all achieved GVHD CR on day+15. Due to manufacturer
discontinuation of the IV formulation, we amended the
protocol to use PO LBH589. Using 10mg PO thrice weekly 48
hours apart for 4 weeks, we treated 2 subjects which both
discontinued study drug due to GHVD progression within 7
days of LBH589. Due to safety concerns, the next group
received a reduced dose of 5 mg PO thrice weekly x 4 (Level
-1). Thus far we have accrued 4 subjects at this dose. By day
+8, the GVHD responsewas PR¼2 and CR¼2with all in GVHD
CR on day+15. Toxicities include reversible thrombocyto-
penia and neutropenia grade 1-2 (CTCAE 4) possibly related
to study drug. The overall GVHD CR rate of 80% by day +15 in
our initial cohort is encouraging, suggesting a role for HDACi
LBH589 as a tool to improve success of corticosteroids for
GVHD treatment. Correlative studies are planned to address
pharmacodynamics of LBH589 on inﬂammatory cytokines, to
correlate DAC enzymatic activity inhibition with clinicalNon-relapse mortality
p overall
p
Value n HR, 95% CI p
0.01 0 1132 1.0
0.002 1 292 2.34 (1.24-4.43) 0.009
0.09 2 93 2.55 (1.03-6.30) 0.04
0.04 3 22 5.17 (1.34-19.87) 0.02
